Nestled in a quiet industrial park in Redmond, Washington, not too far from the Microsoft headquarters, is a small biotech start-up with both an interesting technology they are bringing to market, as well as a capital partner that suggests some ways in which global biotech research, venture capital and commercialization are going to change. The company is Cerevast Therapeutics, the manufacturer of a non-invasive medical device that treats acute ischemic stroke through the use of acoustic energy delivered from a device the patient wears on their head immediately after they get to a stroke center and begin the IV delivery of blood-clot dissolving medicine. The device utilizes sixteen ultrasound transducers that project localized energy into the brain to disrupt blood clots where acute ischemic strokes occur through a process known as sonothrombolysis.
Hey, check out all the engineering jobs. Post your resume today!
